Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

In this Phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate (CR+PR) was 42 percent* (n=24) as assessed by independent review at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Detailed clinical data, including CA 19-9 and pharmacodynamic results will be presented at the meeting.

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 depletes this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu , M.D., Ph.D., Vice President, Oncology Clinical Development,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)...  ( www.competitivehealth.com ) — Competitive Health is pleased ... and advocacy service, has signed an agreement to become ... health services marketplace. 63% of Americans have ... expected to pay. As part of an ongoing effort ... is pleased to offer medical bill review and negotiation ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a ... a network of more than 20 contributing fertility ... fast access to a national pool of frozen ... Associates of Memphis is the only fertility clinic in ... Dr. William Kutteh , director of Fertility Associates ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... the quarter ended December,31, 2007, on February 8. The ... Hosting the call will be Paul E. Freiman, ... President and Chief Financial Officer.,The details for the call ...
... Pain ... Products, FREDERICK, Md., ... signed a,sales, marketing and distribution agreement with Locin Industries, Ltd,Vancouver, Canada., ... health products, medical devices, and health and,beauty aids. Locin has over 30 ...
... and Texas Instruments have unveiled a new chip design ... times more energy-efficient than present technology. The design could ... that last far longer when running from a battery. ... at the International Solid-State Circuits Conference in San Francisco ...
Cached Biology Technology:BioElectronics Announces Canadian Retail Product Launch 2Team develops energy-efficient microchip 2
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... millions of dollars are typically the costs, when companies ... to a treatment are welcome. Researchers at Department of ... a potential short cut. "Our new research shows, ... faster and cheaper than usual in the development of ...
... animals must explore their world to find the necessities of ... a mental map of their environment to navigate the safest ... to anticipate when and where certain important events, such as ... the connection between these two fundamental behaviors, navigation and the ...
... the occurrence and development of depression, and can be ... have shown that miR-137 expression is downregulated in the ... expression is also downregulated in peripheral blood from stroke ... are associated with post-stroke depression. To test this, Dr. ...
Cached Biology News:Genetic aberration paves the way for new treatment of cancer disease 2Anticipation and navigation: Do your legs know what your tongue is doing? 2Anticipation and navigation: Do your legs know what your tongue is doing? 3Anticipation and navigation: Do your legs know what your tongue is doing? 4
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: